IXI
NEUTRALIXICO Grants Share Options to Leadership Team
The healthcare technology company has issued 1.4 million share options to its leadership team, with vesting criteria linked to retention and revenue growth.
IXICO
11.75GBX
0.00%
Market Cap
10.89M
Volume
2k
3% of avg
P/E Ratio
-5.60
EPS (TTM)
-2.1
Beta
0.38
Day Range
11.99p - 11.99p
52 Week Range
7.35p11.75p15.00p
11.75p
Upcoming Events
IXI
NEUTRALIXICO Reports 13% Revenue Growth and Reduced EBITDA Loss in 2025 Results
The neuroscience imaging and biomarker analytics provider reported 13% revenue growth and reduced EBITDA loss, alongside an expanding order book and diversification into new therapeutic areas.
IXI
GOODIXICO Strengthens Scientific Advisory Board with Alzheimer's and Vascular Experts
The healthcare company has appointed two leading global experts in Alzheimer's Disease and cerebrovascular disease to its Scientific Advisory Board, strengthening its capabilities in these key therapeutic areas.
IXI
NEUTRALIXICO Provides Notice of 2025 Full Year Results and Investor Presentation
The healthcare company announces upcoming full year results and an investor presentation, providing an opportunity for shareholders to engage with management.
IXI
VERY GOODIXICO Secures £3.5M Global Phase 3 Clinical Trial Contract
The healthcare technology company has secured a major new contract worth over £3.5 million to provide imaging services for a global Phase 3 clinical trial in Huntington's Disease, further strengthening its position in the neurological disease research market.
IXI
NEUTRALIXICO Provides Capital Markets Day Update
The healthcare technology company has shared a recording of its recent Capital Markets Day presentation, highlighting its progress and future strategy.
IXI
VERY GOODIXICO Delivers Double-Digit Revenue Growth in FY25
The healthcare technology company reported double-digit revenue growth and improved profitability in its latest trading update, signaling strong execution of its strategic plan.
IXI
GOODIXICO Secures £1.2 Million in New Contracts and Extensions
The healthcare technology company has secured a new contract and contract extension worth a total of £1.2 million, demonstrating its expertise in neuroscience imaging and biomarker analytics.
IXI
NEUTRALIXICO Announces Capital Markets Day
The healthcare technology company is hosting a Capital Markets Day for analysts and investors to discuss its growth strategy and technology platform.
IXI
GOODIXICO Secures £1.3 Million in New Neuroscience Imaging Contracts
The healthcare technology company has secured two new contracts worth a combined £1.3 million to provide neuroimaging services for clinical trials in Alzheimer's Disease and Friedreich's Ataxia.